Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2019. The report serves as a notification of a transaction involving a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR), specifically an award of ordinary shares under the Company's Share Value Plan.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a specific equity transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Award of Ordinary Shares under the Share Value Plan.
- Volume: 6,330 shares.
- Price: £17.434 per share.
- Transaction Date: September 3, 2019.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not disclose material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents a routine equity award transaction for a PCA (Mr. D. Jackson, associated with Ms. S. Jackson, SVP, Global Communications and CEO Office).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, contingencies, or discussion of unusual items. The document is strictly a regulatory disclosure of a specific share award event.
Investor Verification Points
- Verify the total number of shares awarded to the PCA and their aggregate value based on the reported price of £17.434.
- Confirm the identity of the PCA (Mr. D. Jackson) and their relationship to the PDMR (Ms. S. Jackson) as disclosed.
- Note that this filing does not contain financial performance data; refer to GSK's Form 20-F or quarterly earnings releases for revenue and profit metrics.